Post-transplant lymphoproliferative disorder - The potential of proliferation signal inhibitors

Nephrology Dialysis Transplantation

Volumn 22, Issue SUPPL. 1, 2007, Pages

  Pascual, Julio ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Post transplant lymphoproliferative disorder; Post transplant malignancy; Proliferation signal inhibitors mammalian target of rapamycin inhibitors; Renal transplant recipients

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CD20 ANTIBODY; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; EVEROLIMUS; INSULIN; INTERLEUKIN 2 RECEPTOR ANTIBODY; LYMPHOCYTE ANTIBODY; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISOLONE; PREDNISONE; RAPAMYCIN; RITUXIMAB; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; VINCRISTINE; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE;

ACUTE GRAFT REJECTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURGERY; CARCINOGENESIS; CHRONIC GRAFT REJECTION; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GROWTH INHIBITION; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL PNEUMONIA; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MONOTHERAPY; NEPHROTIC SYNDROME; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; DRUG EFFECT; REVIEW; SIGNAL TRANSDUCTION;

HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; PROTEIN KINASES; SIGNAL TRANSDUCTION; SIROLIMUS;

EID: 34250156714     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfm088     Document Type: Article

References (23)

1. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am J Transplant 2004; 4: 905-913
2. Capello D, Rossi D, Gaidano G. Post-transplant lymphoproliferative disorders: Molecular basis of disease histogenesis and pathogenesis. Hematol Oncol 2005; 23: 61-67
3. Morrison VA, Dunn DL, Manivel JC, Gajl-Peczalska KJ, Peterson BA. Clinical characteristics of post-transplant lymphoproliferative disorders. Am J Med 1994; 97: 14-24
4. Opelz G, Dohler B. Lymphomas after solid organ transplantation: A collaborative transplant study report. Am J Transplant 2003; 4: 222-230
5. LaCasce AS. Post-transplant lymphoproliferative disorders. Oncologist 2006; 11: 674-680
6. Pascual J, Torrelo A, Teruel JL et al. Cutaneous T cell lymphomas after renal transplantation. Transplantation 1992; 53: 1143-1145
7. Smith JM, Rudser K, Gillen D et al. Risk of lymphoma after renal transplantation varies with time: An analysis of the United States Renal Data System. Transplantation 2006; 81: 175-180
8. Flanagan KH, Brennan DC. EBV-associated recurrent Hodgkin's disease after renal transplantation. Transpl Int 2006; 19: 338-341
9. Walker RC, Marshall WF, Strickler JG et al. Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis 1995; 20: 1346-1353
10. Boubenider S, Hiesse C, Goupy C, Kriaa F, Marchand S, Charpentier B. Incidence and consequences of post-transplantation lymphoproliferative disorders. J Nephrol 1997; 10: 136-145
11. Caillard S, Dharnidharka V, Agodoa L, Bohen E, Abbott K. Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation 2005; 80: 1233-1243
12. Robson R, Cecka JM, Opelz G, Budde M, Sacks S. Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. Am J Transplant 2005; 5: 2954-2960
13. Pirsch JD. Cytomegalovirus infection and posttransplant lymphoproliferative disease in renal transplant recipients: Results of the U.S. multicenter FK506 Kidney Transplant Study Group. Transplantation 1999; 68: 1203-1205
14. Birkeland SA, Hamilton-Dutoit S. Is posttransplant lymphoproliferative disorder (PTLD) caused by any specific immunosuppressive drug or by the transplantation per se? Transplantation 2003; 76: 984-988
15. Morath C, Mueller M, Goldschmidt H et al. Malignancy in renal transplantation. J Am Soc Nephrol 2004; 15: 1582-1588
16. Ramsay HM, Fryer AA, Reece S et al. Clinical risk factors associated with nonmelanoma skin cancer in renal transplant recipients. Am J Kidney Dis 2000; 36: 167-176
17. Fortina AB, Piaserico S, Caforio AL et al. Immunosuppressive level and other risk factors for basal cell carcinoma and squamous cell carcinoma in heart transplant recipients. Arch Dermatol 2004; 140: 1079-1085
18. Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993; 342: 1514-1516
19. Melosky B, Karim M, Chui A et al. Lymphoproliferative disorders after renal transplantation in patients receiving triple or quadruple immunosuppression. J Am Soc Nephrol 1992; 212 [Suppl]: S290-S294
20. Majewski M, Korecka M, Kossev P et al. The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. Proc Natl Acad Sci USA 2000; 97: 4285-4290
21. Majewski M, Korecka M, Joergensen J et al. Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses. Transplantation 2003; 75: 1710-1717
22. Nepomuceno RR, Balatoni CE, Natkunam Y et al. Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein-Barr virus B-cell lymphomas. Cancer Res 2003; 63: 4472-4480
23. Cullis B, D'Souza R, McCullagh P et al. Sirolimus-induced remission of posttransplantation lymphoproliferative disorder. Am J Kidney Dis 2006; 47: E67-e72